Chief Executive Officer, Novartis
Appears in 1 story
Leading company through back-to-back clinical setbacks
Novartis' experimental muscle-disease drug del-desiran failed its phase 3 Harbor trial, missing the primary endpoint and sending shares down. The drug was the centerpiece of the company's $12 billion acquisition of Avidity Biosciences, which closed last year.
Updated 3 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
